Exact Sciences’ Oncodetect MRD Test Gains Medicare Coverage for Colorectal Cancer

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received Medicare coverage. The coverage was granted through the Centers for Medicare & Medicaid Services’/CMS Molecular Diagnostic Services Program/MolDX for serial use in patients with stage II, III, and resectable stage IV colorectal cancer/CRC.

The coverage extends to both adjuvant and recurrence monitoring settings over 5 years. The Medicare coverage for colorectal cancer addresses a substantial need, as more than 3 million Americans are eligible for MRD testing across various solid tumors.

Exact Sciences' Oncodetect MRD Test Gains Medicare Coverage for Colorectal Cancer

A surgeon wearing a medical mask, examining a cancer patient in a surgical facility.

The Oncodetect test is a highly sensitive, tumor-informed assay that empowers oncologists and patients with critical insights throughout their treatment journey. It is capable of tracking up to 200 circulating tumor DNA/ctDNA)variants and can detect signs of cancer recurrence up to 2 years earlier than traditional imaging methods alone.

Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening and diagnostic test products in the US and internationally. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University.

While we acknowledge the potential of EXAS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EXAS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.